Link Details
- Metabolite
- HMDB0000067 (Cholesterol)
- DrugBank ID
- DB01076
- Drug Name
- Atorvastatin
- Effect
- Decrease
- Biospecimen
- Blood
- P-value
- Not Available
- Beta Estimator
- Not Available
- Percent Change
- Not Available
- Pearson Correlation Coefficient
- Not Available
- Comments
- Not Available
- Gomez-Gerique JA, Ros E, Olivan J, Mostaza JM, Vilardell M, Pinto X, Civeira F, Hernandez A, da Silva PM, Rodriguez-Botaro A, Zambon D, Lima J, Diaz C, Aristegui R, Sol JM, Chaves J, Hernandez G: Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia. Atherosclerosis. 2002 Jun;162(2):245-51. [PubMed:11996943 ]
- Chan DC, Watts GF, Barrett PH, Beilin LJ, Redgrave TG, Mori TA: Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia. Diabetes. 2002 Aug;51(8):2377-86. [PubMed:12145148 ]
- Chan DC, Watts GF, Nguyen MN, Barrett PH: Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity. Am J Clin Nutr. 2006 Jul;84(1):37-43. [PubMed:16825679 ]
- Lea AP, McTavish D: Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias. Drugs. 1997 May;53(5):828-47. [PubMed:9129869 ]